PMID- 30382950
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1473-6551 (Electronic)
IS  - 1350-7540 (Linking)
VI  - 31
IP  - 6
DP  - 2018 Dec
TI  - Stimulation of N-methyl-D-aspartate receptors by exogenous and endogenous ligands 
      improves outcome of brain injury.
PG  - 687-692
LID - 10.1097/WCO.0000000000000612 [doi]
AB  - PURPOSE OF REVIEW: The failure of N-methyl-D-aspartate receptor (NMDAR) 
      antagonists as a treatment for human traumatic brain injury (TBI) and stroke, 
      along with preclinical findings of a persistent hypofunctional state of these 
      receptors after brain injury, resulted in a new focus on NMDAR agonists, 
      specifically those acting via the glycine site of the NMDAR. This article reviews 
      the recent literature on positive modulators of the glycine site as a new 
      modality for improving cognitive function in central nervous system pathology, 
      including traumatic and ischemic brain injuries, neuroinflammation, and 
      neuropsychiatric disorders. RECENT FINDINGS: A sustained cognitive decline and 
      NMDAR downregulation were reported in rodent models of TBI, developmental TBI, 
      stroke, and lipopolysaccharide-induced neuroinflammation. Activation of the 
      glycine/serine site by D-cycloserine (DCS) or D-serine ameliorated these 
      cognitive deficits. Recent reviews and reports on the use of DCS and D-serine to 
      modify memory function in a wide range of psychiatric conditions are generally 
      positive. SUMMARY: Taken together, the preclinical and clinical studies provide 
      new, additional support for the notion that activation of the glycine/serine site 
      should be considered a novel therapeutic approach to cognitive impairments. 
      Specifically, as DCS is an approved drug, its translation into clinical practice 
      should be advocated.
FAU - Biegon, Anat
AU  - Biegon A
AD  - Department of Radiology and Neurology, Stony Brook University School of Medicine, 
      Stony Brook, New York, USA.
FAU - Liraz-Zaltsman, Sigal
AU  - Liraz-Zaltsman S
AD  - Department of Pharmacology, Institute for Drug Research, Hebrew University, 
      Jerusalem, Israel.
AD  - The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan.
AD  - Faculty of Health Profession, Ono Academic College, Kiryat Ono, Israel.
FAU - Shohami, Esther
AU  - Shohami E
AD  - Department of Pharmacology, Institute for Drug Research, Hebrew University, 
      Jerusalem, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Curr Opin Neurol
JT  - Current opinion in neurology
JID - 9319162
RN  - 0 (Ligands)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
SB  - IM
MH  - Animals
MH  - Brain Injuries, Traumatic/*drug therapy
MH  - Humans
MH  - Ligands
MH  - Receptors, N-Methyl-D-Aspartate/*agonists
MH  - Treatment Outcome
EDAT- 2018/11/02 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/11/02 06:00
PHST- 2018/11/02 06:00 [entrez]
PHST- 2018/11/02 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
AID - 00019052-201812000-00005 [pii]
AID - 10.1097/WCO.0000000000000612 [doi]
PST - ppublish
SO  - Curr Opin Neurol. 2018 Dec;31(6):687-692. doi: 10.1097/WCO.0000000000000612.